<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578028</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-2808-01</org_study_id>
    <secondary_id>2019-004693-26</secondary_id>
    <nct_id>NCT04578028</nct_id>
  </id_info>
  <brief_title>A First in Human Study to Assess the Safety,Tolerability and Pharmacokinetics of ONO-2808 in Healthy Participants</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled, Single Centre, Four-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2808 in Non-Japanese and Japanese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in human study to determine the safety, tolerability and pharmacokinetics of&#xD;
      ONO-2808 in healthy adult participants. The study will be conducted in 4 parts: Part A, a&#xD;
      single-ascending dose part with an assessment of the potential food effects in non-Japanese&#xD;
      adult participants; Part B, a single-dose part to assess the effect of age in non-Japanese&#xD;
      elderly participants; Part C, a multiple-ascending dose part with ONO-2808 administered to&#xD;
      non-Japanese adult participants; and Part D, a single and multiple doses part to assess the&#xD;
      ethnicity difference between Japanese and non-Japanese healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">August 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events (TEAEs) by severity.</measure>
    <time_frame>Part A and B: up to day 7; Part C: up to 17 days; Part D single dose: up to 7 days; Part D multiple dose: at least 17 days and up to 24 days.</time_frame>
    <description>Number of participants with TEAEs. An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possible causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>Part A and B: up to day 7; Part C: up to 17 days; Part D single dose: up to 7 days; Part D2 multiple dose: at least 17 days and up to 24 days.</time_frame>
    <description>Number of participants with SAEs. An SAE is any untoward medical occurrence that at any dose results in death; is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs (number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate and blood pressure)</measure>
    <time_frame>Part A and B: up to day 7; Part C: up to 17 days; Part D1 single dose: up to 7 days; Part D2 multiple dose: at least 17 days and up to 24 days.</time_frame>
    <description>Summary statistics of vital signs and number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate, and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG parameters (number of participants with ECG abnormalities)</measure>
    <time_frame>Part A and B: up to day 7; Part C: up to 17 days; Part D1 single dose: up to 7 days; Part D2 multiple dose: at least 17 days and up to 24 days.</time_frame>
    <description>Number of participants with ECG abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests (number of participants with clinical laboratory abnormalities (including haematology, clinical chemistry and urinalysis))</measure>
    <time_frame>Part A and B: up to day 7; Part C: up to 17 days; Part D single dose: up to 7 days; Part D multiple dose: at least 17 days and up to 24 days.</time_frame>
    <description>Number of participants with clinical laboratory abnormalities (including haematology, clinical chemistry and urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination (number of participants with physical examination abnormalities)</measure>
    <time_frame>Part A and B: up to day 7; Part C: up to 17 days; Part D single dose: up to 7 days; Part D multiple dose: at least 17 days and up to 24 days.</time_frame>
    <description>Number of participants with physical examination abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological examination (number of participants with neurological examination abnormalities)</measure>
    <time_frame>Part A and B: up to day 7; Part C: up to 17 days; Part D single dose: up to 7 days; Part D multiple dose: at least 17 days and up to 24 days.</time_frame>
    <description>Number of participants with neurological examination abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with suicidal behaviour</measure>
    <time_frame>Part C: up to 17 days, Part D multiple dose: at least 17 days and up to 24 days</time_frame>
    <description>Treatment-emergent suicidal ideation and behaviour will be monitored by using the Columbia Suicide Severity Rating Scale (C-SSRS) and reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 7, Part C: Day 1 and 14, Part D single dose: Day 1 through to 7 &amp; Part D multiple dose: Day 1 and Day 14</time_frame>
    <description>Assessment of the maximum observed plasma concentration of ONO-2808</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 7, Part C: Day 1 and 14, Part D single dose: Day 1 through to 7 &amp; Part D multiple dose: Day 1 and Day 14</time_frame>
    <description>Assessment of the time to reach Tmax for ONO-2808</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUClast)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 7, Part D single dose: Day 1 through to 7</time_frame>
    <description>Assessment of the area under the concentration-time curve of ONO-2808 to last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUCinf)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 7, Part D single dose: Day 1 through to Day 7</time_frame>
    <description>Assessment of the area under the concentration-time curve of ONO-2808 extrapolated to infinite time in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUCtau)</measure>
    <time_frame>Part C: Day 1 and Day 14, Part D multiple dose: Day 1 and Day 14</time_frame>
    <description>Assessment of the area under the concentration-time curve of ONO-2808 during the dosing interval in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 7, Part D single dose: Day 1 through to Day 7</time_frame>
    <description>Assessment of the terminal elimination half-time of ONO-2808 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (CL/F)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 7, Part D single dose: Day 1 through to Day 7</time_frame>
    <description>Assessment of the apparent clearance of ONO-2808 from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Vz/F)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 7, Part D single dose: Day 1 through to Day 7</time_frame>
    <description>Assessment of the apparent volume of distribution of ONO-2808 during terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Aetz)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 5, Part C: Day 1, 8 &amp; 14, Part D single dose: Day 1 through to Day 5, Part D multiple dose: Day 1 and 14</time_frame>
    <description>Assessment of the amount of ONO-2808 excreted in urine over the period of sample collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Percentage fe)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 5, Part C: Day 1, 8 &amp; 14, Part D single dose: Day 1 through to Day 5, Part D multiple dose: Day 1 and 14</time_frame>
    <description>Assessment of the cumulative percentage of orally administered ONO-2808 excreted into urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (CLR)</measure>
    <time_frame>Part A &amp; B: Day 1 through Day 5, Part C: Day 1, 8 &amp; 14, Part D single dose: Day 1 through to Day 5, Part D multiple dose: Day 1 and 14</time_frame>
    <description>Assessment of the renal clearance of ONO-2808 from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of ONO-2808 to the brain</measure>
    <time_frame>Part A (in selected fasted cohorts): Day 1 and 2, Part C: Day 1 and Day 14</time_frame>
    <description>Assessment of ONO-2808 brain distribution by measuring drug concentration in the cerebro spinal fluid (CSF)</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Neurodegenerative Diseases</condition>
  <arm_group>
    <arm_group_label>ONO-2808 Part A - Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of ONO-2808 or placebo orally under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Placebo Part A- Fasted</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose of ONO-2808 or placebo orally under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Part A - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of ONO-2808 or placebo orally under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Placebo Part A - Fed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of ONO-2808 or placebo orally under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Placebo Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of ONO-2808 or placebo orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Placebo Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending doses of ONO-2808 or placebo orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single or multiple doses of ONO-2808 or placebo in Japanese healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-2808 Placebo Part D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single or multiple doses of ONO-2808 or placebo in Japanese healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2808</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>ONO-2808 Part A - Fasted</arm_group_label>
    <arm_group_label>ONO-2808 Part A - Fed</arm_group_label>
    <arm_group_label>ONO-2808 Part B</arm_group_label>
    <arm_group_label>ONO-2808 Part C</arm_group_label>
    <arm_group_label>ONO-2808 Part D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug</description>
    <arm_group_label>ONO-2808 Placebo Part A - Fed</arm_group_label>
    <arm_group_label>ONO-2808 Placebo Part A- Fasted</arm_group_label>
    <arm_group_label>ONO-2808 Placebo Part B</arm_group_label>
    <arm_group_label>ONO-2808 Placebo Part C</arm_group_label>
    <arm_group_label>ONO-2808 Placebo Part D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide fully informed written consent.&#xD;
&#xD;
          2. 18-55 years (Part A &amp; C), or ≥65 years (Part B) or 20-55 years (Part D).&#xD;
&#xD;
          3. Non-Japanese male and female participants (Women of non-child bearing potential&#xD;
             (WONCBP)) (Part A, B &amp; C) or male and female participants (WONCBP) of Japanese&#xD;
             ethnicity (Part D).&#xD;
&#xD;
          4. Agree to use an effective method of contraception.&#xD;
&#xD;
          5. No clinically significant medical history and no abnormal physical examination,&#xD;
             laboratory profiles, vital signs or ECG abnormalities, based on the Screening&#xD;
             examination.&#xD;
&#xD;
          6. Body mass index of ≥18.5 to &lt;30 kg/m2 and a body weight of at least 50 kg for males&#xD;
             and 45 kg for females to a maximum of 100 kg, at the time of screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of clinically significant medical, surgical or psychiatric&#xD;
             condition (including history of suicidal behaviour) or objection by General&#xD;
             Practitioner (GP) to participant entering trial.&#xD;
&#xD;
          2. Sensitivity to the study drug.&#xD;
&#xD;
          3. Female who is pregnant or lactating or of childbearing potential.&#xD;
&#xD;
          4. History or presence of alcoholism or drug/chemical/substance abuse.&#xD;
&#xD;
          5. Use of any medication which may affect ONO-2808 pharmacokinetics or pharmacodynamics&#xD;
&#xD;
          6. Current smoker or has smoked (including use of tobacco and/or nicotine-containing&#xD;
             products) in the previous 3 months&#xD;
&#xD;
          7. Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg) or hepatitis C virus (HCV).&#xD;
&#xD;
          8. Vital signs and supine resting blood pressure outside the acceptable normal range&#xD;
&#xD;
          9. Participants who are not willing to eat a high fat breakfast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo F Soto, MD,MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ono Pharma UK LTD</last_name>
    <phone>+44 (0) 207421 4920</phone>
    <email>ctinfo@ono-uk.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parexel International Early Phase Clinical Unit (EPCU)</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo F Soto, MD,MSc,PhD</last_name>
      <phone>+44 189 561-4355</phone>
      <email>Pablo.ForteSoto@PAREXEL.com</email>
    </contact>
    <investigator>
      <last_name>Pablo F Forte, MD,MSc,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurodegenerative diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

